Equity Profile

CGON

CG Oncology, Inc.

Health CareBiotechnology$6.6B

Aug7Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of the company's profitability and financial health.

$-0.82

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$1M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. As part of the health care sector, its advancements could significantly impact patient outcomes and the overall market for cancer therapies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In the last quarter, CG Oncology reported an EPS of $-0.71, which was lower than the expected $-0.58. The stock reacted positively, increasing by 0.64% the following day.

Management Promises & Guidance

Focus on advancing clinical trials.
Commitment to improving operational efficiency.
Plans to enhance product pipeline.

Expectations

Wall Street Expectations

Analysts expect CG Oncology to report a loss this quarter, with a consensus EPS of $-0.82. Revenue expectations are modest, reflecting ongoing challenges in the biotech space.

Bull Case

If the company can exceed EPS expectations and show signs of revenue growth, it may indicate a turnaround in its financial performance, boosting investor confidence.

Bear Case

A larger-than-expected loss or stagnant revenue could raise concerns about the company's viability and future prospects, leading to a negative market reaction.

Key Metrics to Watch

EPS

$-0.82

Earnings per share is a critical indicator of the company's profitability and financial health.

Revenue

$1M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CG Oncology's EPS come in better than the consensus estimate of $-0.82?

A better-than-expected EPS could indicate improved operational efficiency and market confidence.

What revenue figures will CG Oncology report, and how do they compare to the $1M consensus?

Revenue performance is crucial for assessing market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for CG Oncology to exceed revenue expectations due to recent advancements in its clinical trials.

Supporting Evidence

The company has shown resilience in past quarters, often surprising analysts with better-than-expected results.

Options pricing suggests a high volatility expectation, indicating that traders may anticipate a significant move.

Recent trends in biotech suggest a rebound in investor sentiment, which could favor CG Oncology.

Key Risk

If the company reports revenue significantly above $1M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CG Oncology can improve its financial performance amidst ongoing challenges in the biotech sector.

Bull Confirmed If

An EPS of $-0.66 or better, along with revenue exceeding $1M, would confirm the bull case.

Bear Confirmed If

An EPS of $-0.96 or worse, with revenue falling below $1M, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±36.98%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders anticipate volatility around the earnings announcement.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests the stock could rise by around 0.10% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary.

Miss

A miss could lead to a decline of approximately 0.79% based on past performance, raising concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials and their potential impact on revenue.
2Any new partnerships or collaborations that could enhance market presence.
3Management's outlook on future product launches and their expected timelines.
4Insights into cost management strategies and operational efficiencies.
5Responses to market competition and how the company plans to differentiate its offerings.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

BP p.l.c.

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a critical indicator of the company's profitability and financial health.

$-0.82

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$1M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In the last quarter, CG Oncology reported an EPS of $-0.71, which was lower than the expected $-0.58. The stock reacted positively, increasing by 0.64% the following day.

Management Promises & Guidance

Focus on advancing clinical trials.
Commitment to improving operational efficiency.
Plans to enhance product pipeline.

Expectations

Wall Street Expectations

Analysts expect CG Oncology to report a loss this quarter, with a consensus EPS of $-0.82. Revenue expectations are modest, reflecting ongoing challenges in the biotech space.

Bull Case

If the company can exceed EPS expectations and show signs of revenue growth, it may indicate a turnaround in its financial performance, boosting investor confidence.

Bear Case

A larger-than-expected loss or stagnant revenue could raise concerns about the company's viability and future prospects, leading to a negative market reaction.

Key Metrics to Watch

EPS

$-0.82

Earnings per share is a critical indicator of the company's profitability and financial health.

Revenue

$1M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CG Oncology's EPS come in better than the consensus estimate of $-0.82?

A better-than-expected EPS could indicate improved operational efficiency and market confidence.

What revenue figures will CG Oncology report, and how do they compare to the $1M consensus?

Revenue performance is crucial for assessing market demand and the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for CG Oncology to exceed revenue expectations due to recent advancements in its clinical trials.

Supporting Evidence

The company has shown resilience in past quarters, often surprising analysts with better-than-expected results.

Options pricing suggests a high volatility expectation, indicating that traders may anticipate a significant move.

Recent trends in biotech suggest a rebound in investor sentiment, which could favor CG Oncology.

Key Risk

If the company reports revenue significantly above $1M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CG Oncology can improve its financial performance amidst ongoing challenges in the biotech sector.

Bull Confirmed If

An EPS of $-0.66 or better, along with revenue exceeding $1M, would confirm the bull case.

Bear Confirmed If

An EPS of $-0.96 or worse, with revenue falling below $1M, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±36.98%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders anticipate volatility around the earnings announcement.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests the stock could rise by around 0.10% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary.

Miss

A miss could lead to a decline of approximately 0.79% based on past performance, raising concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials and their potential impact on revenue.
2Any new partnerships or collaborations that could enhance market presence.
3Management's outlook on future product launches and their expected timelines.
4Insights into cost management strategies and operational efficiencies.
5Responses to market competition and how the company plans to differentiate its offerings.